

Recent Peer-Reviewed Publications Relevant to Vosoritide for Achondroplasia

International Guidelines and Recommendations

International Consensus Guidelines on the Implementation and Monitoring of Vosoritide Therapy in Individuals With Achondroplasia.

[Savarirayan R, Hoover-Fong J, Ozono K, et al.](#)

Nat Rev Endocrinol. 2025;21:314–24

Considerations for Anthropometry Specific to People with Disproportionate Short Stature.

[Hoover-Fong J, Semler O, Barron B, et al.](#)

Adv Ther. 2025;42:1291–1311

Clinical Trial Data

Sustained Growth-Promoting Effects of Vosoritide in Children With Achondroplasia from an Ongoing Phase 3 Extension Study.

[Savarirayan R, Irving M, Wilcox WR, et al.](#)

Med. 2024:100566

Persistent Growth-Promoting Effects of Vosoritide in Children With Achondroplasia are Accompanied by Improvements in Physical and Social Aspects of Health-Related Quality of Life.

[Savarirayan R, Irving M, Wilcox WR, et al.](#)

Genet Med. 2024;26:101274

Real-World Evidence^a

Real-World Safety and Effectiveness of Vosoritide in Children With Achondroplasia: French Early Access Program.

[Cormier-Daire V, Edouard T, Isidor B, et al.](#)

Horm Res Paediatr. 2025:1–9

Changes in the Alignment of the Spine and Lower Limb in Children With Achondroplasia Treated With Vosoritide: A Single-center, 1-year Follow-up Prospective Study.

[Sawamura K, Kitoh H, Kamiya Y, et al.](#)

J Pediatr Orthop. 2025:April 15 Online ahead of print

Real-world Outcome of Vosoritide Treatment in Children With Achondroplasia: A 12-month Retrospective Observational Study.

[Reincke S, Semler O, Junghänel-Welzing S, et al.](#)

J Endocr Soc. 2025;9:bvaf041

Real-world Safety and Effectiveness of Vosoritide in Achondroplasia: Results from a Single Center in Portugal.

[Rua IB, Silva I, Beger C, et al.](#)

Adv Ther. 2025:June 5 Online ahead of print

^aCriteria for inclusion was studies with more than 10 individuals, therefore, this may not represent a comprehensive list of available information.

Recent peer-reviewed publications are defined as within the last 12 months

If you would like a copy of the publication, please contact us at medinfo@bmrn.com or through our web request form.

B:OMARIN[®]

Developed and funded by BioMarin – October 2025 | MED-BM-0061